Rejected Compounds Clause Samples

The 'Rejected Compounds' clause defines how certain chemical compounds or substances are excluded from further consideration or development within a contractual relationship, typically in the context of pharmaceutical or chemical research agreements. This clause outlines the criteria or process by which a party can designate a compound as rejected, such as failing to meet specified performance benchmarks or safety standards. Its core practical function is to provide a clear mechanism for managing and documenting which compounds are no longer part of the collaboration, thereby preventing disputes and ensuring both parties focus resources on viable candidates.
Rejected Compounds. Except to the extent prohibited by any other written agreement between the Parties, Idenix may, in its sole discretion and without any obligation to Novartis, determine whether and how (itself or through Third Parties) to develop, commercialize and/or manufacture any Rejected Compound and products derived therefrom anywhere in the world; provided, however, that if Novartis believes in good faith that Idenix did not offer to Novartis the right to obtain a license to any compound Controlled by Idenix as required hereunder, or that any license, or any option or other right to obtain a license, granted hereunder to Novartis with respect to such compound have not terminated or expired, then in each case the provisions of Section 13.6 shall apply and such compound shall not be deemed a Rejected Compound unless it is so determined in accordance with the procedures set forth in Section 13.6.
View SourceView Similar (2)
Rejected Compounds. (a) Compounds which the Joint Research Committee determines meet Research Target Profile but which are not accepted by ZENECA for development as Development Candidates will continue to be owned in their entirety by ISIS. [ * ] (b) [ * ] (c) [ * ] * CONFIDENTIAL TREATMENT REQUESTED
View SourceView Similar (2)
Rejected Compounds. (a) Compounds which the Joint Research Committee determines meet Research Target Profile but which are not accepted by ZENECA for development as Development Candidates will continue to be owned in their entirety by ISIS. However, ISIS will not have the right to develop, commercialize or sublicense any such Compounds for so long as ZENECA has an Active Target Program for the Target for such Compound. (b) [ * ] * CONFIDENTIAL TREATMENT REQUESTED (c) At the time ZENECA ceases to have an Active Target Program, such Target will be considered an Abandoned Target and ISIS will be free to develop and commercialize any Compound inhibiting such Target fully with, subject to Paragraph 3.4
View SourceView Similar (2)
Rejected Compounds. In the event that a Compound (or in the case of a PoC Trial, a Candidate Selection Compound) becomes a Rejected Compound in accordance with the procedure set forth in Sections 2(c)v.B, 2(c)v.C and/or 2(c)vi.D, SGI will continue to conduct research and development activities on another Compound in accordance with the Research Plan and the guidelines set forth in Section 2(b) during the Research Term. If a Rejected Compound is [***] with a Licensed Compound, then upon GSK’s exercise of the GSK Option, such Rejected Compound shall be licensed to GSK as part of the License. If a Rejected Compound is not [***] with a Licensed Compound, then it shall remain with SGI for its own purposes, subject to Section 2(f).
View Source
Rejected Compounds. If, within one (1) year following Achillion’s notice to FOB of the designation of a Clinical Candidate, Achillion has not used Commercially Reasonable Efforts to Develop or Commercialize such Clinical Candidate or is not continuing to do so (each such compound, a “Rejected Compound”), the license grants under Section 2.1 shall terminate with respect to such Rejected Compound and Achillion shall thereafter have no further rights with respect to such Rejected Compound. Notwithstanding the preceding sentence, Achillion shall retain its rights hereunder with respect to all Licensed Compounds other than Rejected Compounds, including any Compound Modification relating to a Rejected Compound that is also a Compound Modification of a Licensed Compound.
View Source

Related to Rejected Compounds

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Product NYISO will provide Energy Resource Interconnection Service and Capacity Resource Interconnection Service to Developer at the Point of Interconnection.

  • Licensed Product The term “Licensed Product” shall mean any product (a) the manufacture, use, importation, sale or offer for sale of which would, in the absence of the license granted by this Agreement, infringe a Valid Claim of any of the Licensed Patent Rights, or (b) that is comprised of, utilizes or incorporates Licensed Biological Materials, or (c) that is discovered, developed or made using a Licensed Process.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.